Roivant Sciences (ROIV) Change in Accured Expenses (2020 - 2026)

Roivant Sciences (ROIV) has 6 years of Change in Accured Expenses data on file, last reported at -$3.9 million in Q4 2025.

• Quarterly Change in Accured Expenses rose 80.01% year-over-year to -$3.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$35.9 million (up 30.67% YoY) and the FY2025 annual result came in at -$10.1 million, down 321.87% from the prior year.
• Change in Accured Expenses declined to -$3.9 million in Q4 2025, from $12.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $37.6 million in Q3 2023 to a low of -$50.0 million in Q2 2023.
• A 5-year average of -$1.3 million and a median of -$3.9 million in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2021 — Change in Accured Expenses soared 281.76% — and 2023, when it tumbled 376.83%.
• Tracing ROIV's Change in Accured Expenses over 5 years: stood at $35.6 million in 2021, then slumped by 83.97% to $5.7 million in 2022, then slumped by 376.83% to -$15.8 million in 2023, then decreased by 23.58% to -$19.5 million in 2024, then surged by 80.01% to -$3.9 million in 2025.
• The last three Change in Accured Expenses figures came in at -$3.9 million (Q4 2025), $12.5 million (Q3 2025), and -$25.0 million (Q2 2025), per Business Quant data.